Stroke Prevention by ORal Thrombin Inhibition V "SPORTIF V"

Completed

Phase N/A Results

Summary of Purpose

To compare the safety and efficacy of an oral direct thrombin inhibitor (ximelagatran) with those of warfarin (coumadin) in preventing stroke and systemic embolic events in patients with atrial fibrillation.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 4 September 2008.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • AstraZeneca

Trial Design

Randomized, open-label, parallel-group study, double blind, double-dummy treatment allocation and computerized algorithms to generate sham INR data.

Contacts

Not available